Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Claris Lifesciences Ltd

    Claris Lifesciences Ltd is a multi-business enterprise and the Holding Company of Claris Injectables, a wholly-owned subsidiary dealing in Specialty Injectables business, colle

  • No Image
    Colabs Pharma

    Colabs Pharma is a platform for discovery, applied research management, chemical and pharmaceutical supply chain connectivity.

  • No Image
    Colinz Laboratories Ltd

    Colinz Laboratories Ltd., was incorporated in the year 1986, is manufacturing and marketing various allopathic and Ayurvedic pharmaceutical formulations in the dosage forms of t

  • No Image
    Concord Drugs Ltd

    Concord Drugs Ltd was established in 1995, is engaged in manufacturing of Finished Pharmaceutical Formulations like Injectables (Small volume parenterals, Dry powder ) ,Tissue B

  • No Image
    Coral Laboratories Ltd

    Coral Laboratories has an ultra modern manufacturing units in Daman, Dehradun and Vasai.